Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortizatization of Intangibles (2016 - 2024)

Akebia Therapeutics (AKBA) has disclosed Amortizatization of Intangibles for 8 consecutive years, with $9.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Amortizatization of Intangibles changed 0.0% to $9.0 million in Q4 2024 year-over-year; TTM through Sep 2025 was $9.0 million, a 75.0% decrease, with the full-year FY2024 number at $36.0 million, changed 0.0% from a year prior.
  • Amortizatization of Intangibles was $9.0 million for Q4 2024 at Akebia Therapeutics, roughly flat from $9.0 million in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $9.1 million in Q1 2020 to a low of $16000.0 in Q4 2020.
  • A 5-year average of $8.4 million and a median of $9.0 million in 2021 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: crashed 99.96% in 2020, then soared 56418.75% in 2021.
  • Akebia Therapeutics' Amortizatization of Intangibles stood at $16000.0 in 2020, then skyrocketed by 56418.75% to $9.0 million in 2021, then decreased by 0.12% to $9.0 million in 2022, then decreased by 0.24% to $9.0 million in 2023, then changed by 0.0% to $9.0 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Amortizatization of Intangibles are $9.0 million (Q4 2024), $9.0 million (Q3 2024), and $9.0 million (Q2 2024).